{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:25:49Z","timestamp":1794446749582,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This systematic review investigates the effect of small interfering RNA (siRNA) therapies on lipoprotein(a) [Lp(a)] levels. The purpose is to evaluate the outcomes of recent randomized controlled trials (RCTs) involving siRNA treatments aimed at lowering Lp(a) levels, a known cardiovascular risk factor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive search across multiple databases was conducted, identifying 20 published and ongoing RCTs that examined the effects of siRNA therapies such as inclisiran, olpasiran, and SLN360 on Lp(a) levels. The included studies were analyzed to assess Lp(a) reductions and other lipid-related outcomes. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The RCTs demonstrated significant reductions in Lp(a) levels following siRNA therapy. Additional reductions were noted in LDL-c and apolipoprotein B levels. Side effects were typically mild, including injection site reactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>siRNA therapies show promise in effectively lowering Lp(a) levels, with minimal adverse effects. However, further research is required to establish their long-term safety and efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43044-025-00635-1","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:56:13Z","timestamp":1746698173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Small interfering RNA effect on lipoprotein(a): a systematic review"],"prefix":"10.1186","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-6255","authenticated-orcid":false,"given":"Omar","family":"Almaadawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mar\u2019ey","family":"Hesn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yomna Ayman","family":"Elsalamony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Ayman","family":"Abobakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman Hossam","family":"Elshimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled Alsayed","family":"Abulkhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Mohamed","family":"Negm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Yasser","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakubu","family":"Bene-Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Annie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ramy","family":"Elashery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"635_CR1","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547760\/."},{"issue":"12","key":"635_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K et al (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316(12):1289\u20131297. https:\/\/doi.org\/10.1001\/jama.2016.13985","journal-title":"JAMA"},{"issue":"23","key":"635_CR3","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.3390\/jcm11237249","volume":"11","author":"S Aygun","year":"2022","unstructured":"Aygun S, Tokgozoglu L (2022) Comparison of current international guidelines for the management of dyslipidemia. J Clin Med 11(23):7249. https:\/\/doi.org\/10.3390\/jcm11237249","journal-title":"J Clin Med"},{"key":"635_CR4","unstructured":"Force M. 2019 esc\/eas guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2019. https:\/\/boris.unibe.ch\/1493."},{"key":"635_CR5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-031023-100609","author":"E Tasdighi","year":"2023","unstructured":"Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ (2023) LP(a): structure, genetics, associated cardiovascular risk, and emerging therapeutics. Annu Rev Pharmacol Toxicol. https:\/\/doi.org\/10.1146\/annurev-pharmtox-031023-100609","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"635_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0787-7","volume":"15","author":"A Sahebkar","year":"2017","unstructured":"Sahebkar A, Simental Mendia LE, Watts GF, Serban C, Banach M (2017) Comparison of the effects of fibrates versus statins on plasma lipoprotein (a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med 15(1):1\u201314. https:\/\/doi.org\/10.1186\/s12916-017-0787-7","journal-title":"BMC Med"},{"key":"635_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200173","volume":"16","author":"B Zafrir","year":"2023","unstructured":"Zafrir B, Aker A, Saliba W (2023) Extreme lipoprotein(a) in clinical practice: a cross sectional study. Int J Cardiol Cardiovasc Risk Prev 16:200173. https:\/\/doi.org\/10.1016\/j.ijcrp.2023.200173","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"24","key":"635_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","volume":"74","author":"DF Gudbjartsson","year":"2019","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J et al (2019) Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 74(24):2982\u20132994","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"635_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","volume":"13","author":"DP Wilson","year":"2019","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG et al (2019) Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 13(3):374\u2013392. https:\/\/doi.org\/10.1016\/j.jacl.2019.04.010","journal-title":"J Clin Lipidol"},{"issue":"11","key":"635_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11883-021-00968-7","volume":"23","author":"NC Henney","year":"2021","unstructured":"Henney NC, Banach M, Penson PE (2021) RNA silencing in the management of dyslipidemias. Curr Atheroscler Rep 23(11):69. https:\/\/doi.org\/10.1007\/s11883-021-00968-7","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"635_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012502.pub2","volume":"11","author":"S Zhan","year":"2018","unstructured":"Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X (2018) Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 11(11):CD012502. https:\/\/doi.org\/10.1002\/14651858.CD012502.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"635_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","volume":"349","author":"GG Schwartz","year":"2022","unstructured":"Schwartz GG, Ballantyne CM (2022) Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis 349:110\u2013122","journal-title":"Atherosclerosis"},{"issue":"2","key":"635_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","volume":"13","author":"H Dana","year":"2017","unstructured":"Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, Mehmandoost N, Moazzen F, Mazraeh A, Marmari V, Ebrahimi M, Rashno MM, Abadi SJ, Gharagouzlo E (2017) Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci IJBS 13(2):48\u201357","journal-title":"Int J Biomed Sci IJBS"},{"issue":"10","key":"635_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11883-022-01056-0","volume":"24","author":"A Pirillo","year":"2022","unstructured":"Pirillo A, Catapano AL (2022) Inclisiran: How widely and when should we use it? Curr Atheroscler Rep 24(10):803\u2013811","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"635_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4274\/tmsj.galenos.2023.2023-5-1","volume":"10","author":"ME K\u0131l\u0131\u00e7","year":"2023","unstructured":"K\u0131l\u0131\u00e7 ME (2023) PCSK9 siRNA inhibitor inclisiran as a treatment option in hypercholesterolemia: a brief review. Turk Med Stud J 10(3):105\u2013111","journal-title":"Turk Med Stud J"},{"issue":"1","key":"635_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12265-014-9605-1","volume":"8","author":"T-S Marija","year":"2015","unstructured":"Marija T-S, Robinson M, Voci LL, Andrews L, Satya Y, Williams S et al (2015) Development of Lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis. J Cardiovasc Transl Res 8(1):44\u201353","journal-title":"J Cardiovasc Transl Res"},{"key":"635_CR17","unstructured":"Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies."},{"issue":"21","key":"635_CR18","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ (2023) Lepodisiran, an extended-duration short interfering RNA targeting Lipoprotein(a): a randomized dose-ascending clinical trial. JAMA 330(21):2075\u20132083. https:\/\/doi.org\/10.1001\/jama.2023.21835","journal-title":"JAMA"},{"key":"635_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"635_CR20","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. URL https:\/\/www.R-project.org\/."},{"key":"635_CR21","unstructured":"Cochrane. Cochrane handbook for systematic reviews of interventions. 2022. Available at: https:\/\/training.cochrane.org\/handbook\/current. Accessed 5 Jan 2023."},{"issue":"20","key":"635_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEjMoa2211023","volume":"387","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS, OCEAN(a)-DOSE Trial Investigators (2022) Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease. N Engl J Med 387(20):1855\u20131864. https:\/\/doi.org\/10.1056\/NEjMoa2211023","journal-title":"N Engl J Med"},{"issue":"17","key":"635_CR23","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C et al (2022) Single ascending dose study of a short interfering RNA targeting Lipoprotein(a) production in individuals with elevated plasma Lipoprotein(a) levels. JAMA J Am Med Assoc 327(17):1679\u20131687","journal-title":"JAMA J Am Med Assoc"},{"issue":"16","key":"635_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ et al (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 382(16):1507\u20131519","journal-title":"N Engl J Med"},{"issue":"16","key":"635_CR25","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS et al (2020) Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 382(16):1520\u20131530","journal-title":"N Engl J Med"},{"issue":"48","key":"635_CR26","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ et al (2022) Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 43(48):5047\u20135057","journal-title":"Eur Heart J"},{"key":"635_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10557-022-07413-0","volume":"8","author":"W Koenig","year":"2022","unstructured":"Koenig W, Conde LG, Landmesser U, Leiter LA, Ray KK, Schwartz GG et al (2022) Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials. Cardiovasc Drugs Ther 8:493\u2013553. https:\/\/doi.org\/10.1007\/s10557-022-07413-0","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"635_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","volume":"44","author":"W Sohn","year":"2022","unstructured":"Sohn W, Winkle P, Neutel J, Wu Y, Jabari F, Terrio C et al (2022) Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study. Clin Ther 44(9):1237\u20131247. https:\/\/doi.org\/10.1016\/j.clinthera.2022.07.008","journal-title":"Clin Ther"},{"issue":"1","key":"635_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376(1):41\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1609243","journal-title":"N Engl J Med"},{"key":"635_CR30","unstructured":"Evaluate SLN360 in participants with elevated Lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ongoing randomized controlled trial). 2023. Retrieved from clinical trial.gov (identifier: NCT05537571)."},{"key":"635_CR31","unstructured":"Olpasiran trials of cardiovascular events and LipoproteiN(a) reduction\u2014DOSE finding study (ongoing randomized controlled trials. 2020. Retrieved from clinical trial.gov (identifier: NCT04270760)."},{"key":"635_CR32","unstructured":"Olpasiran trials of cardiovascular events and Lipoprotein(a) reduction (OCEAN(a))\u2014outcomes trial (ongoing randomized controlled trial). 2022. Retrieved from clinical trial.gov (identifier: NCT05581303)."},{"key":"635_CR33","unstructured":"Study of efficacy and safety of inclisiran in Asian participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD high risk and elevated low density lipoprotein cholesterol (LDL-C) (ongoing study). 2021. Retrieved from clinical trial.gov (identifier: NCT04765657)."},{"key":"635_CR34","unstructured":"Efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated low-density lipoprotein cholesterol. (V-Mono China) (ongoing randomized controlled trial). 2023. Retrieved from clinical trial.gov (identifier: NCT05888103)."},{"key":"635_CR35","unstructured":"A study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of olpasiran in Chinese participants with elevated serum Lipoprotein(a) (ongoing randomized controlled trial). 2021. Retrieved from clinicaltrials.gov (identifier: NCT04987320)."},{"key":"635_CR36","unstructured":"Study to evaluate efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolemia (ORION-16) (ongoing randomized controlled trial). 2021. Retrieved from clinical trial.gov (identifier: NCT04652726)."},{"key":"635_CR37","unstructured":"Study to evaluate efficacy and safety of inclisiran in adolescents with homozygous familial hypercholesterolemia (ORION-13) (ongoing randomized controlled trials). 2021. Retrieved from clinical trial.gov (identifier: NCT04659863)."},{"key":"635_CR38","unstructured":"Study to investigate safety, tolerability, PK and PD response of SLN360 in subjects with elevated Lipoprotein(a) (ongoing randomized controlled trial). 2021. Retrieved from clinical trial.gov (identifier: NCT04606602)."},{"key":"635_CR39","unstructured":"Study to evaluate efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolemia (ongoing randomized controlled trial). 2020. Retrieved from WHO international trials (identifier: EUCTR2020-002757-18-SI)."},{"key":"635_CR40","unstructured":"Study to evaluate efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolemia (ongoing randomized controlled trials). 2021. Retrieved from WHO international trials (identifier: LBCTR2021034776)."},{"issue":"16","key":"635_CR41","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK et al (2020) Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 382(16):1520\u20131530. https:\/\/doi.org\/10.1056\/NEJMoa1913805","journal-title":"N Engl J Med"},{"issue":"21","key":"635_CR42","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X et al (2023) Lepodisiran, an extended-duration short interfering RNA targeting Lipoprotein(a): a randomized dose-ascending clinical trial. JAMA 330(21):2075\u20132083","journal-title":"JAMA"},{"issue":"5","key":"635_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017470","volume":"10","author":"P Finneran","year":"2021","unstructured":"Finneran P, Pampana A, Khetarpal SA, Trinder M, Patel AP, Paruchuri K, Aragam K, Peloso GM, Natarajan P (2021) Lipoprotein(a) and coronary artery disease risk without a family history of heart disease. J Am Heart Assoc 10(5):e017470. https:\/\/doi.org\/10.1161\/JAHA.120.017470","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"635_CR44","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.3390\/ijerph20186721","volume":"20","author":"P Vinci","year":"2023","unstructured":"Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G (2023) Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health 20(18):6721. https:\/\/doi.org\/10.3390\/ijerph20186721","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"635_CR45","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12016-017-8611-x","volume":"54","author":"AA Momtazi","year":"2018","unstructured":"Momtazi AA, Banach M, Pirro M, Stein EA, Sahebkar A (2018) MicroRNAs: New therapeutic targets for familial hypercholesterolemia? Clin Rev Allergy Immunol 54(2):224\u2013233","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"635_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcla.24552","volume":"36","author":"R Chen","year":"2022","unstructured":"Chen R, Lin S, Chen X (2022) The promising novel therapies for familial hypercholesterolemia. J Clin Lab Anal 36(7):1\u201313","journal-title":"J Clin Lab Anal"},{"issue":"18","key":"635_CR47","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","volume":"78","author":"J Brandts","year":"2021","unstructured":"Brandts J, Ray KK (2021) Familial Hypercholesterolemia: JACC focus seminar 4\/4. J Am Coll Cardiol 78(18):1831\u20131843","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"635_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110641","volume":"27","author":"Y Luo","year":"2024","unstructured":"Luo Y, Hou Y, Zhao W, Yang B (2024) Recent progress in gene therapy for familial hypercholesterolemia treatment. iScience 27(9):110641. https:\/\/doi.org\/10.1016\/j.isci.2024.110641","journal-title":"iScience"},{"key":"635_CR49","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation 139:e1082\u2013e1143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625","journal-title":"Circulation"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-025-00635-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:56:22Z","timestamp":1746698182000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-025-00635-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1186\/s43044-025-00635-1","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}